证券代码：000566 证券简称：海南海药 公告编号：2025-050 海南海药股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、特别提示： 1、本次股东大会无否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议的情形。 二、会议召开的情况 1、召开时间： 现场会议召开时间：2025年7月23日下午15：00 网络投票时间：2025年7月23日 3、召开方式：采用现场表决与网络投票相结合的方式召开 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025年7月23日 9：15～9：25，9：30～11：30和13：00～15：00； （2）通过深圳证券交易所互联网投票系统投票的时间为：2025年7月23日9:15～ 15:00期间的任意时间。 2、召开地点：海南省海口市秀英区南海大道 192 号海药工业园公司会议室 4、召集人：公司第十一届董事会 5、现场会议主持人：公司第十一届董事会董事长王建平先生 6、公司部分董事、监事和高级管理人员现场或通过视频方式出席了本次股东大会， 北京大成(海口 ...

北京大成（海口）律师事务所 关于海南海药股份有限公司2025年第三次临时股东大会的 法 律 意 见 书 大成isDentons' PreferredLawFirminChina. 北京大成（海口）律师事务所 北京大成（海口）律师事务所 关于海南海药股份有限公司2025年第三次临时股东大会 的法律意见书 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范性文件的 要求，北京大成（海口）律师事务所（以下简称"本所"）接受海南海药股份有限 公司（以下简称"公司"）的委托，指派律师参加公司2025年第三次临时股东大 会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集、召开程序、出席会议人员资格 、召集人资格、表决程序、表决结果发表法律意见，并不对本次股东大会所审议 的议案、议案所涉及的事项及内容发表意见。本所律师同意将本法律意见书随本 次股东大会其他信息披露资料一并公告。 本法律意见书仅供见证公司本次股东大会相关事项的合法性之目的使用，不 得 ...

Market Performance - The Hainan Free Trade Zone concept declined by 4.19%, ranking among the top declines in concept sectors as of July 23 [1] - Notable stocks that hit the daily limit down include Hainan Ruize and Caesar Travel, while Hainan Strait Holdings and Hainan Highway experienced significant declines [1] - Only two stocks within the sector saw price increases, with Lishang Guochao rising by 5.18% and Hainan Huatie by 1.04% [1] Capital Flow - The Hainan Free Trade Zone concept experienced a net outflow of 3.679 billion yuan, with 27 stocks seeing net outflows and 13 stocks exceeding 100 million yuan in net outflows [1] - Hainan Huatie led the outflow with 920 million yuan, followed by Hainan Development, Caesar Travel, and Hainan Highway with outflows of 297 million yuan, 288 million yuan, and 254 million yuan respectively [1] - The stocks with the highest net inflows included Lishang Guochao and ST Huawen, with inflows of 36.78 million yuan and 1.12 million yuan respectively [1] Stock Performance Details - Hainan Huatie had a price change of 1.04% with a turnover rate of 23.47% and a net outflow of 919.67 million yuan [2] - Hainan Development saw a decline of 3.64% with a turnover rate of 18.83% and a net outflow of 296.70 million yuan [2] - Caesar Travel experienced a significant drop of 9.94% with a turnover rate of 23.44% and a net outflow of 288 million yuan [2]

Group 1 - The Hainan Free Trade Zone concept rose by 2.76% as of the close on July 17, ranking 8th among concept sectors, with 28 stocks increasing in value [1] - Notable performers within the Hainan Free Trade Zone sector included Caesar Travel, which hit the daily limit, and Hainan Haiyao, Hainan Ruize, and Hainan Qiche Group, which rose by 6.75%, 6.73%, and 6.49% respectively [1] - The sector saw a net inflow of 845 million yuan from main funds, with 21 stocks receiving net inflows, and 8 stocks attracting over 30 million yuan each [2] Group 2 - The top net inflow stock was Hainan Huatie, with a net inflow of 299 million yuan, followed by Caesar Travel, Junda Co., and Hainan Haiyao with net inflows of 150 million yuan, 87 million yuan, and 85 million yuan respectively [2][3] - The net inflow ratios for Caesar Travel, Hainan Mining, and HNA Holding were 37.54%, 12.28%, and 11.60% respectively, indicating strong interest from main funds [3] - The trading volume and turnover rates for key stocks in the Hainan Free Trade Zone included Hainan Huatie at 18.52% turnover and a 4.95% increase, while Caesar Travel had a turnover of 6.64% and a 10.07% increase [3][4]

Group 1 - The A-share market in Hainan Free Trade Zone is experiencing a volatile upward trend, with significant gains in various stocks [1] - Caesar Travel Industry has reached a daily limit increase, indicating strong investor interest [1] - Jun Da Co., Ltd. has risen over 5.5%, reflecting positive market sentiment [1] Group 2 - Hainan Haiyao and Lishang Guochao have both increased by more than 3%, contributing to the overall positive performance of the sector [1] - Haikong Group and other related companies are also seeing upward movement, suggesting a broader rally in the Hainan Free Trade Zone stocks [1]

Core Viewpoint - Hainan Haiyao Co., Ltd. has transformed its R&D innovation system, focusing on both innovative and generic drug development, while actively expanding its product lines in the health sector through a combination of in-house R&D and external partnerships [1][2]. Group 1: R&D and Product Development - The company has significantly increased its R&D investment, adhering to a strategy of "combining imitation and innovation," leading to substantial progress in generic drugs and formulations [1]. - Recent achievements include the successful consistency evaluation of injectable cefoperazone sodium, enhancing market competitiveness, and the registration approval of linezolid tablets, expanding the raw material drug product line [1]. - Since 2021, Hainan Haiyao has passed consistency evaluations for 18 varieties and 38 specifications of generic drugs, improving overall drug quality [1]. Group 2: Innovative Drug Development - Hainan Haiyao is advancing two Class 1 innovative drugs, including the anti-fibrosis drug fluvoxamine capsules, which has reached the primary endpoint in Phase II clinical trials and is set to enter Phase III trials [2]. - The company is also developing an anti-epileptic drug, paenagabin tablets, with a significant patient base in China, where approximately 9 million people suffer from epilepsy, indicating a substantial market opportunity [2]. Group 3: International Collaboration - Leveraging the advantages of the Hainan Free Trade Port, Hainan Haiyao has established exclusive distribution agreements with AFT Pharmaceuticals Ltd., enhancing its product pipeline in the health sector [3]. - The collaboration includes innovative dietary supplements and a long-acting injection for schizophrenia, expanding the company's offerings in the neuropsychiatric field [3]. Group 4: Traditional Chinese Medicine - Hainan Haiyao has a long history of exploring traditional remedies, developing modern strategies to enhance the value of classic formulas [4]. - The company has achieved multiple registrations and patents for its flagship product, Fengliao Gastrointestinal Health series, and plans to strengthen its gastrointestinal product line [4]. Group 5: Future Outlook - The company aims to continue selecting traditional Chinese medicine projects and establish a modern production platform, fostering the growth of its TCM segment [4]. - Hainan Haiyao is well-positioned to integrate classic formulas with modern technology, expanding its reach in the health sector and providing innovative health solutions to consumers [4][5].

Performance Forecast - The company expects a net loss attributable to shareholders of between 120 million and 160 million yuan, compared to a loss of 200.31 million yuan in the same period last year [1] - The net loss after deducting non-recurring gains and losses is estimated to be between 140 million and 170 million yuan, compared to a loss of 153.07 million yuan in the previous year [1] - The basic earnings per share are projected to be a loss of between 0.0925 yuan and 0.1233 yuan, compared to a loss of 0.1544 yuan per share last year [1] Reasons for Performance Change - The decrease in loss is attributed to cost reduction and efficiency improvement measures implemented by the company, along with a reduction in market development expenses due to the implementation of industry policies [1] - The company reported an increase in investment income from trading financial assets compared to the previous year, which contributed to the performance improvement [2]

[Hainan Haiyao 2025 Semi-Annual Performance Forecast](index=1&type=section&id=%E6%B5%B7%E5%8D%97%E6%B5%B7%E8%8D%AF%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) [Performance Forecast Overview](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates continued losses in the first half of 2025, but with a significant narrowing of the loss compared to the same period last year, with net profit attributable to shareholders expected to be a loss of 120 million to 160 million yuan, compared to a loss of 200.31 million yuan in the prior year period Key Financial Performance Indicators | Item | Current Period (2025 H1) | Prior Year Period (2024 H1) | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Loss: 120 - 160 million yuan | Loss: 200.31 million yuan | | **Net Profit After Non-Recurring Items** | Loss: 140 - 170 million yuan | Loss: 153.07 million yuan | | **Basic Earnings Per Share** | Loss: 0.0925 - 0.1233 yuan/share | Loss: 0.1544 yuan/share | [Analysis of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The narrowing of losses this period is primarily due to effective cost reduction and control measures, leading to a significant year-on-year decrease of approximately 60 million yuan in selling expenses, and an increase of approximately 46 million yuan in investment income due to the absence of debt restructuring losses incurred in the prior year period - Selling expenses decreased year-on-year: Current period selling expenses are estimated at approximately **86 million yuan**, a decrease of approximately **60 million yuan** compared to the prior year period, primarily due to the company's cost reduction and control initiatives and industry policy impacts[5](index=5&type=chunk) - Investment income increased year-on-year: Current period investment income is estimated at approximately **-5 million yuan**, an increase of approximately **46 million yuan** compared to the prior year period, mainly because a **39 million yuan** debt restructuring loss recognized in the prior year period did not recur this period[5](index=5&type=chunk) [Other Important Notes](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E7%9A%84%E6%83%85%E5%86%B5) The company emphasizes that the financial data in this performance forecast is a preliminary estimate by the finance department, unaudited by a certified public accountant, with final accurate financial data to be disclosed in the 2025 semi-annual report, and advises investors to be aware of investment risks - The financial data related to this performance forecast has not been audited by a certified public accountant[4](index=4&type=chunk) - This performance forecast represents preliminary estimates by the company's finance department, with specific financial data subject to the company's 2025 semi-annual report[5](index=5&type=chunk)[6](index=6&type=chunk)

证券代码：000566 证券简称：海南海药 公告编号：2025-048 海南海药股份有限公司 关于子公司注射用头孢唑肟钠通过仿制药质量和疗效一致性评价的 公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）全资子公司海口市制药厂有限 公司近日获得国家药品监督管理局核准签发的化学药品"注射用头孢唑肟钠"的 《药品补充申请批准通知书》。现将相关情况公告如下： 一、药品基本情况 （一）药品名称：注射用头孢唑肟钠 剂型：注射剂 规格：0.5g、1.0g、2.0g 受理号：CYHB2450238、CYHB2450239、CYHB2450240 适应症：敏感菌所致的下呼吸道感染、尿路感染、腹腔感染、盆腔感染、败 血症、皮肤软组织感染、骨和关节感染、肺炎链球菌或流感嗜血杆菌所致脑膜炎 和单纯性淋病。 审批结论：经审查，本品通过仿制药质量和疗效一致性评价。 （二）药品的其他相关情况 头孢唑肟钠是一种第三代广谱半合成头孢菌素类抗生素，具有广泛的抗菌谱 和较低的耐药性，适用于敏感菌所致的下呼吸道感染、尿路感染、腹腔感染、盆 腔感染、败血症、 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-047 海南海药股份有限公司 关于子公司获得利奈唑胺片药品注册批件的公告 受理号：CYHS2302666 适应症：本品用于治疗由特定微生物敏感株引起的下列感染：院内获得性肺 炎，社区获得性肺炎，复杂性皮肤和皮肤软组织感染，非复杂性皮肤和皮肤软组 织感染，万古霉素耐药的屎肠球菌感染，包括伴发的菌血症等。 药品上市许可持有人：海口市制药厂有限公司 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）全资子公司海口市制药厂有限 公司近日获得国家药品监督管理局核准签发的化学药品"利奈唑胺片"的《药品 注册证书》。现将相关情况公告如下： 一、药品基本情况 （一）药品名称：利奈唑胺片 剂型：片剂 规格：600mg 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 （二）药品的其他相关情况 利奈唑胺是细菌蛋白质合成抑制剂，可以抑制核糖体 50S 亚基的 mRNA 基因 核苷酸与核糖体的结合，组织细菌形成 7 ...